How to Get Repatha (Evolocumab) in Oregon

What Is Repatha and Why Do Oregon Patients Need It?

Repatha (evolocumab) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors available to clear LDL-C from the bloodstream. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [1].

The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every 2 weeks reduced LDL-C by 59% from baseline compared with placebo and cut the composite risk of cardiovascular death, myocardial infarction, or stroke by 20% (hazard ratio 0.80; 95% CI 0.73 to 0.88; P<0.001) over a median follow-up of 2.2 years [2]. That trial enrolled patients already on optimized statin therapy, so the benefit seen was entirely on top of existing lipid-lowering treatment.

Oregon has approximately 1 in 250 residents affected by familial hypercholesterolemia, consistent with the national FH prevalence estimate of 1 in 250 for heterozygous FH reported by the CDC [3]. Despite that prevalence, the American Heart Association notes that fewer than 10% of FH patients in the United States are properly diagnosed and treated [4]. Repatha directly addresses that treatment gap for Oregonians who cannot reach goal LDL-C on statins alone.

The drug comes in two delivery formats: a 140 mg/mL prefilled autoinjector pen and a 420 mg/3.5 mL single-use on-body infusor for monthly dosing. Both are self-administered subcutaneously at home after a brief training session [1].

How to Get a Repatha Prescription in Oregon

Oregon patients can get a Repatha prescription through three main routes: an in-person visit with a cardiologist or lipid specialist, a visit with a primary care physician, or a telehealth consultation with a licensed Oregon provider.

In-person specialist referral. Cardiologists, lipidologists, and endocrinologists at Oregon Health and Science University (OHSU), Legacy Health, and Providence Health regularly manage PCSK9 inhibitor therapy. A referral from a primary care physician accelerates insurance prior authorization because the chart contains documented statin history and cardiovascular risk data [5].

Primary care prescription. Oregon primary care MDs, DOs, NPs, and PAs all hold prescriptive authority for Repatha under Oregon Revised Statutes Chapter 677 (for physicians) and ORS 678.390 (for nurse practitioners). A primary care visit works well when a patient already has a recent lipid panel and documented statin trial on file.

Telehealth prescription. Oregon permanently codified expanded telehealth prescribing authority after 2020. Senate Bill 1529 (2022) confirmed that Oregon-licensed providers may conduct audio-video visits and issue new prescriptions, including for specialty drugs, without a prior in-person relationship in most clinical situations [6]. Several national telehealth platforms are licensed in Oregon and can initiate Repatha therapy when appropriate lab work is on file.

The prescribing clinician will review your LDL-C history, statin tolerance record, and cardiovascular risk category before submitting the prescription and prior authorization documents simultaneously to your pharmacy benefit manager.

What Labs Are Needed Before Starting Repatha in Oregon?

A fasting lipid panel is the core requirement. Most Oregon insurance plans and the Oregon Health Plan require documentation of at least two LDL-C values above threshold, typically LDL-C above 70 mg/dL for ASCVD patients or above 100 mg/dL for FH patients, despite maximally tolerated statin therapy [7].

The standard pre-treatment lab panel at most Oregon clinics includes:

• Fasting lipid panel (LDL-C, total cholesterol, HDL-C, triglycerides)
• Hepatic function panel (ALT, AST), because statin co-therapy can affect liver enzymes
• Creatine kinase if myopathy symptoms are present
• HbA1c or fasting glucose when metabolic syndrome is suspected
• TSH, because hypothyroidism independently elevates LDL-C [8]

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin therapy plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [7]. Oregon insurance carriers cite this guideline directly in their PA criteria, so having labs that document persistent LDL-C elevation despite statin use is the single most important piece of documentation.

Repeat lipid testing 4 to 12 weeks after starting Repatha confirms the response. FOURIER data showed that 59% LDL-C reduction was consistent from week 4 onward [2].

Prior Authorization for Repatha in Oregon: What to Expect

Prior authorization (PA) is required by virtually every Oregon payer. Get familiar with the three documentation categories every PA packet must contain.

1. Diagnosis documentation. The PA form requires an ICD-10 code: E78.01 (FH, pure hypercholesterolemia) or I25.10 (atherosclerotic heart disease with established ASCVD). Genetic testing confirming an LDLR, APOB, or PCSK9 pathogenic variant strengthens the FH application but is not universally mandated [9].

2. Statin trial documentation. Oregon Health Plan Preferred Drug List criteria require documentation of a trial of high-intensity statin therapy (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for at least 3 months, or documented intolerance with a statin alternative trial [10]. Commercial plans typically mirror that 3-month threshold.

3. LDL-C threshold on therapy. Lab values showing LDL-C at or above the plan-specific threshold while on maximally tolerated therapy must be attached. Oregon Medicaid's Pharmacy and Therapeutics Committee has set the ASCVD threshold at LDL-C of 70 mg/dL or higher [10].

The table below summarizes the PA checklist used by most Oregon commercial and Medicaid payers.

| PA Requirement | Typical Oregon Threshold | |---|---| | Diagnosis (ICD-10) | E78.01 or I25.10 confirmed in chart | | Statin trial duration | 3 months at maximally tolerated dose | | LDL-C on statin (ASCVD) | 70 mg/dL or higher | | LDL-C on statin (FH) | 100 mg/dL or higher | | Ezetimibe trial | Required by most Oregon Medicaid PA criteria | | Prescriber type | MD, DO, NP, or PA licensed in Oregon |

Most Oregon commercial plans complete PA review within 3 to 5 business days for urgent submissions and within 14 days for standard submissions, consistent with Oregon Insurance Division rules under ORS 743B.525 [11]. If denied, Oregon law provides a formal internal appeal right and an independent external review option through the Oregon Insurance Division [11].

Telehealth Providers in Oregon Prescribing Repatha

Oregon's telehealth framework makes it one of the more accessible states for specialty drug management online. A prescribing clinician must hold an active Oregon medical or advanced practice license, conduct a real-time audio-video visit (or synchronous audio-only for patients in underserved areas), document clinical findings, and transmit the prescription electronically to a pharmacy of record [6].

Telehealth visits for Repatha management typically proceed as follows. The patient uploads a recent lipid panel (drawn within 90 days), a list of current medications, and a statement of statin history. The provider reviews the cardiovascular risk score, confirms the ASCVD or FH diagnosis, and completes the PA paperwork electronically the same day. Most Oregon telehealth-initiated PAs route to the patient's existing pharmacy benefit rather than a specialty pharmacy, though specialty pharmacies handle the majority of PCSK9 inhibitor dispensing because of cold-chain storage requirements [12].

Patients in rural Oregon, including areas east of the Cascades where cardiologist density is low, benefit most from this pathway. The Oregon Office of Rural Health identified 21 of Oregon's 36 counties as having a health professional shortage for cardiology services as of 2023 [13].

How Long Does It Take to Receive Repatha in Oregon?

From first telehealth or in-person consultation to the first injection, most Oregon patients wait 2 to 4 weeks. The timeline breaks down roughly as follows.

• Day 1 to 3: Consultation, lab review, PA submission
• Day 3 to 10: Payer PA decision (3 to 5 days for urgent, up to 14 days for standard)
• Day 10 to 18: Specialty pharmacy processing and cold-chain shipment (1 to 3 business days after approval)
• Day 14 to 28: First injection after nurse or pharmacist training call

Amgen's specialty pharmacy network ships Repatha refrigerated in insulated packaging. Patients in Portland, Eugene, Salem, and Bend generally receive shipment within 2 business days of pharmacy processing. Rural ZIP codes may require an additional day [12].

Urgent PA pathways exist when a patient has experienced an acute cardiovascular event. Oregon's emergency PA rule requires payers to provide a 72-hour provisional supply authorization for medically urgent situations [11].

Repatha Cost and Patient Assistance in Oregon

List price for Repatha is approximately $700 per month for the biweekly 140 mg regimen and approximately $700 per month for the monthly 420 mg regimen as of 2025 [1]. Few Oregon patients pay that amount out of pocket.

Commercial insurance copay card. Amgen's Repatha SUPPORT copay card reduces out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. The card is not valid for federal programs, so Oregon Medicaid and Medicare beneficiaries are excluded [14].

Oregon Health Plan (Medicaid). Repatha is on the Oregon Medicaid preferred drug list with PA. Once approved, a 30-day supply costs a beneficiary $4 or less under OHP cost-sharing rules [10].

Medicare Part D. The Inflation Reduction Act cap on Medicare Part D out-of-pocket drug spending ($2,000 annual cap beginning 2025) significantly lowers the burden for Medicare-enrolled Oregonians on PCSK9 inhibitors [15]. Amgen's patient assistance program (Amgen Safety Net Foundation) provides free Repatha to uninsured patients meeting income criteria of at or below 500% of the federal poverty level [14].

GoodRx and discount cards. GoodRx prices for evolocumab in Oregon range from approximately $500 to $580 per month at major chains, still substantially below list price. These discounts cannot be combined with insurance benefits [14].

Can You Transfer a Repatha Prescription to Oregon?

Yes. A prescription for Repatha written in another state is transferable to an Oregon-licensed pharmacy, provided the prescription was issued by a provider licensed in the originating state and meets Oregon pharmacy law requirements under ORS 689.515 [16]. Oregon pharmacies accept electronic transfers from out-of-state pharmacies for Schedule V and non-controlled substances, which includes evolocumab.

The practical caveat: if your Oregon insurance plan differs from your prior plan, a new prior authorization tied to your Oregon payer is almost always required, even if you already have an active prescription. The new PA uses the same documentation as an initial application, so bringing your complete statin history and most recent lipid panel speeds the process.

Some patients who relocate to Oregon from states with active Repatha specialty pharmacy accounts can arrange a direct specialty pharmacy transfer. CVS Specialty, Walgreens Specialty, and Accredo all operate in Oregon and accept prescription transfers for evolocumab [12].

503A Compounding Pharmacies and Evolocumab in Oregon

503A pharmacies in Oregon cannot legally compound evolocumab. The FDA has not placed evolocumab on the 503A bulks list, and the agency's guidance makes clear that compounding a commercially available brand biologic without a valid FDA pathway is prohibited under the Federal Food, Drug, and Cosmetic Act [17]. Oregon's State Board of Pharmacy enforces the same prohibition under OAR 855-019.

Patients should be cautious of any compounding pharmacy claiming to offer a "compounded PCSK9 inhibitor." No compounded alternative to Repatha or Praluent (alirocumab) has received FDA review or approval. The only legitimate evolocumab product for Oregon patients is the Amgen-manufactured Repatha [17].

Monitoring After Starting Repatha in Oregon

After the first injection, most Oregon clinicians follow the monitoring schedule recommended by the ACC/AHA lipid guidelines [7].

• 4 to 12 weeks after initiation: Repeat fasting lipid panel to confirm LDL-C response
• 3 months: Repeat hepatic function panel if on concomitant high-intensity statin
• Every 6 to 12 months: Annual lipid panel and cardiovascular risk reassessment

The FOURIER trial showed that LDL-C reductions were maintained without attenuation over 2.2 years of follow-up, and the FOURIER-OLE open-label extension (median 5 years of total follow-up, N=6,635) confirmed durable LDL-C reduction with no new safety signals [18]. That long-term data provides reassurance for Oregon patients starting what is often a lifelong therapy.

Injection-site reactions occur in approximately 2.1% of evolocumab users versus 1.6% of placebo users in FOURIER, making them the most common adverse effect [2]. Neurocognitive adverse events were evaluated in the EBBINGHAUS substudy (N=1,974) and showed no significant difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery (P<0.001 threshold was not met for cognitive harm) [19].

Summary of the Oregon Access Pathway

Getting Repatha in Oregon follows a predictable sequence. A telehealth or in-person consultation establishes the diagnosis and gathers the lab documentation. The prescriber submits the PA simultaneously with the prescription. The payer reviews within 3 to 14 days. Once approved, a specialty pharmacy ships the refrigerated product, and most Oregon patients have their first dose within 4 weeks of starting the process.

Oregon's permanently expanded telehealth laws and the Oregon Health Plan's coverage of Repatha with PA mean that geography and insurance type are no longer the barriers they once were for PCSK9 inhibitor access. A 59% reduction in LDL-C is a clinically meaningful outcome, and the FOURIER trial's 20% reduction in major cardiovascular events makes this one of the best-evidenced lipid therapies available [2].